Drug Profile
Research programme: cancer therapeutics - Innovation Pharmaceuticals
Alternative Names: KM-3174Latest Information Update: 09 Jun 2017
Price :
$50
*
At a glance
- Originator Cellceutix
- Developer Innovation Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
- 02 Aug 2007 Early research in Cancer in USA (unspecified route)